Ligand Pharmaceuticals

Ligand Pharmaceuticals company information, Employees & Contact Information

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International.

Company Details

Employees
130
Founded
-
Address
555 Heritage Dr, Suite 200,united States
Phone
858-550-7500
Email
jo****@****and.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
ligand.com
HQ
Jupiter, Florida
Looking for a particular Ligand Pharmaceuticals employee's phone or email?

Ligand Pharmaceuticals Questions

News

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 - Yahoo Finance

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 Yahoo Finance

Ligand to Host Investor Day on December 9, 2025 - Sahm

Ligand to Host Investor Day on December 9, 2025 Sahm

Ligand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure Patients - Quiver Quantitative

Ligand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure Patients Quiver Quantitative

Dec. 9, 2025: Ligand Investor Day — Harvard Club NYC, 10:30 a.m.–12:00 p.m. ET; live webcast & replay - Stock Titan

Dec. 9, 2025: Ligand Investor Day — Harvard Club NYC, 10:30 a.m.–12:00 p.m. ET; live webcast & replay Stock Titan

Ligand Pharmaceuticals to Host Investor Day in New York City on December 9, 2025 - Nasdaq

Ligand Pharmaceuticals to Host Investor Day in New York City on December 9, 2025 Nasdaq

Ligand Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2025 - Quiver Quantitative

Ligand Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2025 Quiver Quantitative

Ligand to Unveil New Investment Strategy and Royalty Portfolio Outlook at NYC Investor Day - Stock Titan

Ligand to Unveil New Investment Strategy and Royalty Portfolio Outlook at NYC Investor Day Stock Titan

Ligand to Participate in September Investor Conferences - GlobeNewswire

Ligand to Participate in September Investor Conferences GlobeNewswire

Ligand Pharmaceuticals and Channel Therapeutics Announce $50 Million Merger to Advance ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative

Ligand Pharmaceuticals and Channel Therapeutics Announce $50 Million Merger to Advance ZELSUVMI™ for Molluscum Contagiosum Treatment Quiver Quantitative

Ligand (NASDAQ: LGND) schedules third-quarter 2025 conference call at 8:30 a.m. ET - Stock Titan

Ligand (NASDAQ: LGND) schedules third-quarter 2025 conference call at 8:30 a.m. ET Stock Titan

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - GlobeNewswire

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics GlobeNewswire

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences - GlobeNewswire

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences GlobeNewswire

Ligand Partner SQ Innovation Receives FDA Approval for - GlobeNewswire

Ligand Partner SQ Innovation Receives FDA Approval for GlobeNewswire

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 - GlobeNewswire

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 GlobeNewswire

Ligand Announces Closing of Convertible Senior Notes Offering - GlobeNewswire

Ligand Announces Closing of Convertible Senior Notes Offering GlobeNewswire

Biotech Company Ligand Pharmaceuticals Sets Dual Conference Schedule: Citi BioPharma and H.C. Wainwright - Stock Titan

Biotech Company Ligand Pharmaceuticals Sets Dual Conference Schedule: Citi BioPharma and H.C. Wainwright Stock Titan

Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030 - Quiver Quantitative

Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030 Quiver Quantitative

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - GlobeNewswire

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed GlobeNewswire

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance - GlobeNewswire

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance GlobeNewswire

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ GlobeNewswire

Ligand Pharmaceuticals Boosts 2025 Outlook After Massive 57% Jump in Royalty Revenue - Stock Titan

Ligand Pharmaceuticals Boosts 2025 Outlook After Massive 57% Jump in Royalty Revenue Stock Titan

Ligand Forms $50M Dermatology Powerhouse: First Home-Use Molluscum Treatment Coming - Stock Titan

Ligand Forms $50M Dermatology Powerhouse: First Home-Use Molluscum Treatment Coming Stock Titan

SQ Innovation Receives FDA Approval for Lasix ONYU | LGND Stock News - Stock Titan

SQ Innovation Receives FDA Approval for Lasix ONYU | LGND Stock News Stock Titan

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies - Seeking Alpha

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies Seeking Alpha

Ligand Raises $460M Through Low-Rate Convertible Notes While Buying Back $15M in Stock - Stock Titan

Ligand Raises $460M Through Low-Rate Convertible Notes While Buying Back $15M in Stock Stock Titan

Ligand Secures $400M Convertible Note Deal: Key Terms Reveal 0.75% Rate and $15M Share Buyback - Stock Titan

Ligand Secures $400M Convertible Note Deal: Key Terms Reveal 0.75% Rate and $15M Share Buyback Stock Titan

Earnings call transcript: Ligand Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com

Earnings call transcript: Ligand Pharmaceuticals Q2 2025 beats forecasts, stock rises Investing.com

Groundbreaking Skin Treatment Powers $50M Merger: First-Ever FDA-Approved Home Therapy for Molluscum - Stock Titan

Groundbreaking Skin Treatment Powers $50M Merger: First-Ever FDA-Approved Home Therapy for Molluscum Stock Titan

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires - Business Wire

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires Business Wire

Ligand to Acquire APEIRON Biologics AG for $100 Million - Business Wire

Ligand to Acquire APEIRON Biologics AG for $100 Million Business Wire

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy - Business Wire

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy Business Wire

Nonmonotonic Modulation of the Protein–Ligand Recognition Event by Inert Crowders - ACS Publications

Nonmonotonic Modulation of the Protein–Ligand Recognition Event by Inert Crowders ACS Publications

Ligand Distribution of OmniAb Complete and Business Combination Closed - Business Wire

Ligand Distribution of OmniAb Complete and Business Combination Closed Business Wire

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II - Business Wire

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Business Wire

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement - PR Newswire

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement PR Newswire

Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases - Business Wire

Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases Business Wire

Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies - Business Wire

Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies Business Wire

Ligand to Acquire Pfenex Inc. - Business Wire

Ligand to Acquire Pfenex Inc. Business Wire

Ligand to Report Third Quarter Financial Results on November 9, 2021 - FinancialContent

Ligand to Report Third Quarter Financial Results on November 9, 2021 FinancialContent

Top Ligand Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant